327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
The Readout Loud
00:00
Intro
The hosts share their experiences at the STAT Summit, emphasizing its role in uniting biopharmaceutical industry stakeholders. They delve into pressing issues such as autoimmune disease advancements and supply challenges with Eli Lilly's obesity drug, before transitioning to a discussion on modernizing clinical trials with Regeneron.
Transcript
Play full episode
